MS think that investors under-appreciate $MRK /Ridgeback’s oral antiviral candidate (EIDD-2801) for COVID-19, which has blockbuster potential if successful. COVID-19 patients could take this oral after initial diagnosis to reduce disease severity&amp;risk. Reiterate OW rating on MRK